Pulmonology

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.

Outside of CPAP, what therapies—invasive and non-invasive—exist for patients?

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

Albert Rizzo, MD, the chief medical officer of the American Language Association, answers questions about and discusses the dangers of vaping and e-cigarette use in the latest edition of the DocTalk Podcast.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

A recent analysis that included data on 284 patients found that more than 80% of patients with resistant hypertension also had obstructive sleep apnea.

The biologic becomes the first in its drug class to be indicated for patients aged 6-11 years old with the difficult-to-treat condition.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.

Dr. Rizzo provides a look into the current methods of COPD screening, and how patient treatment potential is changed.

The approval for interstitial lung disease associated with systemic sclerosis or scleroderma makes nintedanib the first therapy for the rare condition.

A new extended trial for the liquid immunotherapy shows two-thirds of allergic children were able to consume at least 750 mg of peanut after 3-5 years.

Particle-depleted diesel exhaust may impair a person's lung function worse than just standard diesel exhaust—while also exposing them to more NO2.

How do at-risk exacerbation patients present, and what developing therapies could benefit them?

Air pollution is driving pediatric risk for lung disease. Are there therapies at hand to address it?